anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The protein encoded by the human gene HEC(highly expressed in cancer) contains a long series of leucine heptad repeats and appears to be crucial for normal mitosis. HEC localizes to the nuclei of interphase cells and redistributes to centromeres during M phase. Ectopic expression of a mutant HEC containing only the heptad repeats results in the inability of cells to divide more than once. Inactivation of HEC results in disordered sister chromatid alignment and separation, as well as in the formation of non viable cells with multiple, fragmented micronuclei. HEC interacts through its leucine heptad repeats with several proteins involved in mitosis, including nek2, sb1.8, and two different regulatory subunits of the 26S proteasome, MSS1 and p45. These biochemical properties of HEC suggest its potential roles in modulating proteins important for spindle attachment to kinetochores, sister chromatic movement, and M phase progression.
Clotrimazole and betamethasone dipropionate cream can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during treatment or after withdrawal of treatment. Cushing’s syndrome and hyperglycemia may also occur due to the systemic effect of corticosteroids while on treatment. Factors that predispose a patient to HPA axis suppression include the use of high-potency steroids, large treatment surface areas, prolonged use, use of occlusive dressing, altered skin barrier, liver failure, and young age. 

Because of the potential for systemic corticosteroid effects, patients may need to be periodically evaluated for HPA axis suppression. This may be done by using the adrenocorticotropic hormone (ACTH) stimulation test. 

In a small trial, clotrimazole and betamethasone dipropionate cream was applied using large dosages, 7 g daily for 14 days (BID) to the crural area of normal adult subjects. Three of the 8 normal subjects on whom clotrimazole and betamethasone dipropionate cream was applied exhibited low morning plasma cortisol levels during treatment. One of these subjects had an abnormal cosyntropin test. The effect on morning plasma cortisol was transient and subjects recovered 1 week after discontinuing dosing. In addition, 2 separate trials in pediatric subjects demonstrated adrenal suppression as determined by cosyntropin testing [see Use in Specific Populations (8.4)].

If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid. 

Pediatric patients may be more susceptible to systemic toxicity due to their larger skin-surface-to-body mass ratios [see Use in Specific Populations (8.4)].
Patients implanted with InSync Model 8040, InSync III Model 8042 , or Medtronic CRT-D system. A total of 1999 subjects were enrolled in the study. Of them, 1738 had successful post market implants of InSync Model 8040 (601 subjects), InSync III Model 8042 (512 subjects) and CRT-D devices (625 subjects). The rest 262 subjects came from two pre-market studies: the MIRACLE study added 141 subjects to InSync Model 8040, and the InSync III study added 121 subjects to the InSync III Model 8042. A total of 1014 subjects completed the study through 36 month follow up. Follow-up of 1000 subjects was required by the FDA to satisfy the conditions of approval.
Embodiments herein describe systems and methods to determine RNA structure and uses thereof. Many embodiments utilize one or more machine learning models to determine an RNA structure. In various embodiments, the machine learning model is trained using experimentally determined RNA structures. Certain embodiments identify one or more ligands or drugs that bind to an RNA structure, which can be used to treat an individual for a disease, disorder, or infection. Various embodiments determine structure of other molecules, including DNA, proteins, small molecules, etc. Further embodiments determine interactions between multiple molecules and/or molecule types (e.g., RNA-RNA interactions, RNA-DNA interactions, DNA-protein interactions, etc.).
OBJECTIVE: Non-invasive biomarkers have recently shown promise for seizure forecasting in people with epilepsy. In this work, we developed a seizure-day forecasting algorithm based on nocturnal sleep features acquired using a smart shirt.
METHODS: Seventy-eight individuals with epilepsy admitted to the Centre hospitalier de l'Université de Montréal epilepsy monitoring unit wore the Hexoskin biometric smart shirt during their stay. The shirt continuously measures electrocardiography, respiratory, and accelerometry activity. Ten sleep features, including sleep efficiency, sleep latency, sleep duration, time spent in non-rapid eye movement sleep (NREM) and rapid eye movement sleep (REM), wakefulness after sleep onset, average heart and breathing rates, high-frequency heart rate variability, and the number of position changes, were automatically computed using the Hexoskin sleep algorithm. Each night's features were then normalized using a reference night for each patient. A support vector machine classifier was trained for pseudo-prospective seizure-day forecasting, with forecasting horizons of 16- and 24-h to include both diurnal and nocturnal seizures (24-h) or diurnal seizures only (16-h). The algorithm's performance was assessed using a nested leave-one-patient-out cross-validation approach.
RESULTS: Improvement over chance (IoC) performances were achieved for 48.7% and 40% of patients with the 16- and 24-h forecasting horizons, respectively. For patients with IoC performances, the proposed algorithm reached mean IoC, sensitivity and time in warning of 34.3%, 86.0%, and 51.7%, respectively for the 16-h horizon, and 34.2%, 64.4% and 30.2%, respectively, for the 24-h horizon.
SIGNIFICANCE: Smart shirt-based nocturnal sleep analysis holds promise as a non-invasive approach for seizure-day forecasting in a subset of people with epilepsy. Further investigations, particularly in a residential setting with long-term recordings, could pave the way for the development of innovative and practical seizure forecasting devices.
PLAIN LANGUAGE SUMMARY: Seizure forecasting with wearable devices may improve the quality of life of people living with epilepsy who experience unpredictable, recurrent seizures. In this study, we have developed a seizure forecasting algorithm using sleep characteristics obtained from a smart shirt worn at night by a large number of hospitalized patients with epilepsy (78). A daily seizure forecast was generated following each night using machine learning methods. Our results show that around half of people with epilepsy may benefit from such an approach.
An experimental study design and an intent-to-treat analysis will be used to determine the effectiveness and cost-effectiveness of telemedicine-based collaborative care relative to practice-based collaborative care. The research setting will be six Community Health Centers located in medically underserved areas of Arkansas which serve rural, low income and minority populations. Potentially eligible patients will be identified through screening by Community Health Centers clinic staff or primary care provider referrals. Patients eligible for the study will be consented and randomized to receive either telemedicine-based or practice-based collaborative care, and followed for 18 months to assess processes and outcomes. On-site clinical staff will screen patients for depression over an 18 month period and refer all patients with clinically significant depression (PHQ9≥10) to the study.

Two types of health care professionals will be involved in the practice-based collaborative care model: 1) primary care providers (MD and RNP); and 2) a depression care manager (LPN or Social Worker). The on-site care managers will provide care management activities by phone or face-to-face.

Five types of health care professionals will be involved in the telemedicine-based collaborative care model: 1) primary care providers (MD and RNP); 2) a depression nurse care manager (RN); 3) clinical pharmacist (PharmD); 4) tele-psychologist (PhD); and 5) a tele-psychiatrist (MD). The primary care providers will be located at the Community Health Centers. The off-site depression care team will be located at the clinics of the University of Arkansas for Medical Sciences, Department of Psychiatry. The on-site primary care providers will prescribe medications and schedule all appointments. The off-site nurse care manager will conduct all care management activities by telephone. The off-site clinical pharmacist will conduct medication histories and provide medication management by telephone. The off-site tele-psychologist will conduct evidence-based psychotherapy (cognitive behavioral therapy) via interactive video. The off-site tele-psychiatrist will conduct interactive-video consultations, train and supervise the depression care team, and conduct provider education.
Techniques are disclosed relating to assay configuration. Assay devices are often used to determine characteristics of test samples, e.g., using polymerase chain reaction (PCR) or Deoxyribonucleic Acid (DNA) melt techniques. Various disclosed techniques allow detailed specification of assay parameters. This may allow user modification of assays and/or assay development by third parties. In embodiments in which assay parameters are specified using a separate device, these techniques may reduce validation requirements resulting from modified assays. In some embodiments, assay configuration information that may be added/removed/modified may include: a sequence of operations, parameters for the sequence of operations, data processing parameters, call logic rules/dependencies, and/or reporting rules.
This is a prospective open-cohort study with annual assessment and reporting of descriptive findings from 5 secondary data sources, US Medicare,Optum Research Database (formerly United HealthCare), Scandinavian national health registry databases, including data from Denmark, Sweden, and Norway. The study period will include up to 10 years in each data system depending on data availability. Descriptive statistics will be used to characterize exposure cohorts with respect to patient characteristics, clinical features, and AESI risk factors. Person-year adjusted AESI incidence rates will be calculated among postmenopausal women, postmenopausal women with osteoporosis, and exposure cohorts. Exploratory analyses comparing incidence rates of AESI in women with PMO adjusting for potential confounders will also be conducted. Descriptive statistics will be used to characterize denosumab utilisation patterns in patients who receive denosumab for PMO and in subjects who receive Prolia therapy for unapproved indications. Subsequent substudies using US data systems were added to describe men with osteoporosis treated with Prolia and men and women who receive Prolia with glucocorticoid exposure.
Delirium is an acute, reversible change in mental status that occurs in over 40% of persons with dementia. Delirium superimposed on dementia (DSD) leads to increased mortality, increased costs, nursing home placement, early re-hospitalization, and functional decline. Delirium in persons with dementia appears to substantially worsen outcomes in persons with dementia- who are already burdened with functional decline. The purpose of this study is to improve nursing detection and management of delirium in persons with dementia and decrease the duration and patient complications of delirium. To achieve these objectives, a multi-component intervention strategy called, Early Nurse Detection of Delirium Superimposed on Dementia (END DSD) will be tested. END-DSD employs a paired cluster randomized trial (C-RCT) of three hospitals with a total of six inpatient units and 360 hospitalized persons with dementia to achieve these objectives. END DSD intervention consists of 1) Nursing education regarding DSD, 2) Computerized decision support through standardized delirium assessment and management screens via the electronic health record (EHR), 3) an identified unit champion on each intervention unit who will be utilized to persuade other nurses to implement the innovation, and 4) Weekly feedback to the nursing staff to further facilitate assessment and management of delirium. We are testing the following specific aims: A.1: To determine whether the intervention "END DSD" improves nurse detection and management of DSD. A.2: To determine the effect of "END DSD" intervention on patient clinical outcomes, including duration of delirium and rate of psychoactive medications.

The study focuses on a costly and prevalent problem, and utilizes a novel approach that via the EHR will clearly be replicable across settings of care. END-DSD has the potential to significantly improve quality of life and decrease costs of care by: improving the detection of DSD; increasing the use of non-pharmacological management of DSD; shortening the duration of delirium and hospital length of stay; and decreasing the use of inappropriate medications, thus mitigating the complications of DSD. This project builds on over a decade of funded research and clinical practice by the investigators, and brings their unique and collaborative efforts together in an innovative manner to impact the under addressed problem of DSD in hospitalized older adults.
FIELD: medicine, particularly, oncology and surgery. SUBSTANCE: upon completion of operation for malignant tumor of abdominal cavity organs, intraoperation intraperitoneal chemotherapy is managed with the help of immobilized cytostatics on solid sorbent in the form of polymethylsiloxane. Cytostatic is used in powdery form. Intraoperation treatment of abdominal cavity is effected, for instance, manually for time sufficient for uniform distribution of cytostatic used in the form of fluorouracil and adriablastin. EFFECT: higher efficient treatment of malignant tumors of abdominal cavity due to reduced time of treatment and decreased complications. 4 cl, 2 tbl
A hydrogel comprising 1,2-diol or 1,3-diol groups acetalised with a radiopaque species, the radiopaque species comprising one or more covalently bound radiopaque halogens. Preferably the radiopaque species is acetalised in the form of a cyclic acetal. The hydrogel may comprise polyvinyl alcohol (PVA). The radiopaque species may be iodine or bromine, preferably iodinated or brominated phenyl groups. The hydrogel may be in the form of a microsphere or microparticle, preferably having a radiopacity of 500HU or greater. A further aspect of the invention is a composition comprising the hydrogel with a therapeutic agent absorbed into the hydrogel matrix. A method of making the radiopaque polymer comprising reacting a polymer comprising 1,2-diol or 1,3-diol groups with a radiopaque species capable of forming a cyclic acetal under acidic conditions. A method of making radiopaque hydrogel microspheres comprising swelling a pre-formed hydrogel microsphere with 1,2-diol or 1,3-diol groups in a solvent, mixing the swollen microsphere with a solution of radiopaque species capable of forming a cyclic acetal under acidic conditions and extracting the microspheres. A method of treatment wherein the hydrogel is administered into a blood vessel to embolise the blood vessel, preferably associated with a solid tumour.
Overdosage experience is limited. In the event of overdosage or an exaggerated response, appropriate supportive measures should be employed. The following measures may be considered: 

Bradycardia - Administer atropine (0.6 to 1 mg). If there is no response to vagal blockade administer isoproterenol cautiously. 

High-degree AV Block - Treat as for bradycardia above. Fixed high-degree AV block should be treated with cardiac pacing. 

Cardiac Failure - Administer inotropic agents (isoproterenol, dopamine, or dobutamine) and diuretics. 

Hypotension - Vasopressors (e.g., dopamine or levarterenol bitartrate). 

The effectiveness of intravenous calcium administration to reverse the pharmacological effects of diltiazem overdose has been inconsistent. In a few reported cases, overdose with calcium channel blockers associated with hypotension and bradycardia that was initially refractory to atropine became more responsive to atropine after the patients received intravenous calcium. In some cases intravenous calcium has been administered (1 g calcium chloride or 3 g calcium gluconate) over 5 minutes, and repeated every 10 to 20 minutes as necessary. Calcium gluconate has also been administered as a continuous infusion at a rate of 2 g per hour for 10 hours. Infusions of calcium for 24 hours or more may be required. Patients should be monitored for signs of hypercalcemia. 

Actual treatment and dosage should depend on the severity of the clinical situation and the judgment and experience of the treating physician. 

Diltiazem does not appear to be removed by peritoneal or hemodialysis. Limited data suggest that plasmapheresis or charcoal hemoperfusion may hasten diltiazem elimination following overdose. 

The intravenous LD50's in mice and rats were 60 and 38 mg/kg, respectively. The toxic dose in man is not known.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to preparation of herbal drugs of broad spectrum of pharmacological effect. A drug for prevention and symptomatic treatment of chronic fatigue syndrome represents mixed dry extracts of Rhaponticum carthamoides rhizomes and roots, ginseng roots, eleutherococcus rhizomes and roots, nettle herb, St. John's wort herb in the ratio 5:2:1:2:1. Said drug can be tabletted. As auxiliary substances, it contains potato starch, calcium stearate, lactose to prepare a tablet of weight 0.15 g. ^ EFFECT: drug is not toxic and makes no irritant action on gastrointestinal mucosa, exhibits general health-improving and adaptogenic action. ^ 2 cl
The present invention discloses a Chinese herb lotion for treating onychomycosis, and a preparation process thereof. The Chinese herb lotion for treating onychomycosis is formed by the following steps: firstly, mixing, heating and distilling walnut tree leaves, willow leaves, peach leaves, capsicum leaves and pepper leaves so as to extract distillate liquid; then, borax, camphor and musk are mixed and pulverized into extremely fine powder; and finally, the distillate liquid and the fine powder are poured into bitter rice wine to be stirred and dissolved. The Chinese herb lotion has the advantages of convenient use, extremely favorable therapeutic effect, less dosage, no toxicity, no harm, etc. The pharmacological experiments indicate that the sterilization rate for dermatophyte in two minutes of the Chinese herb lotion reaches 100%; the clinical experiments indicate that the effectiveness rate reaches 100%, and the cure rate reaches more than 99%. Patients with good condition can be completely cured once with one to two drops smeared. Therefore, the Chinese herb lotion is extremely easy to accept by extensive patients.
In this trial, it is aimed to assess the effectiveness of breathing exercises (BE) for management of labor pain during the second stage of labor. Nulliparous pregnant were randomized two arms. Intervention group received breathing exercise at the first stage of labor. Control group received routine care services. It was conducted at Nenehatun Obstetric and Gynecology Hospital between May-June 2016, in Erzurum, Turkey. Visual Analog Scale (VAS) was performed to identify perception of pain to all pregnant during the second stage of labor. Time of the second stage was recorded as second (sec), and first minute APGAR scores of newborn were recorded. All analysis was carried out using SPSS 20. Significance was set at p\<0.05.
PCT No. PCT/GB95/02875 Sec. 371 Date Jul. 19, 1997 Sec. 102(e) Date Jul. 19, 1997 PCT Filed Dec. 11, 1995 PCT Pub. No. WO96/17951 PCT Pub. Date Jun. 13, 1976A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of: (1) providing a plurality of microorganisms each of which is independently mutated by the insertional inactivation of a gene with a nucleic acid comprising a unique marker sequence so that each mutant contains a different marker sequence, or clones of the said microorganism; (2) providing individually a stored sample of each mutant produced by step (1) and providing individually stored nucleic acid comprising the unique marker sequence from each individual mutant; (3) introducing a plurality of mutants produced by step (1) into the said particular environment and allowing those microorganisms which are able to do so to grow in the said environment; (4) retrieving microorganisms from the said environment or a selected part thereof and isolating the nucleic acid from the retrieved microorganisms; (5) comparing any marker sequences in the nucleic acid isolated in step (4) to the unique marker sequence of each individual mutant stored as in step (2); and (6) selecting an individual mutant which does not contain any of the marker sequences as isolated in step (4).
The present invention discloses an euglena compound tableting candy and a preparation method thereof. The euglena compound tableting candy is prepared from main materials and accessory materials. The main materials consist of chlorella and euglena. The accessory materials consist of sorbitol, xylooligosaccharide, maltodextrin and microcrystalline cellulose. The euglena compound tableting candy consists of the following main and accessory materials in weight percentages: 10-20% of chlorella, 10-20% of euglena, 40-60% of sorbitol, 2% of xylooligosaccharide, 3% of maltodextrin and 15% of microcrystalline cellulose. The preparation method consists of the following main steps: 1. crushing; 2. mixing; 3. granulating; 4. tableting; and 5. packaging. The euglena compound tableting candy has functions of improving organism immunity and activating human body cells. The preparation method is simplified in process, high in efficiency, low in consumption, free of pollution, and economical and convenient.
PURPOSE:To enable early diagnosis of a tuberculosis patient by bringing the sensitized red blood cells obtd. by conjugating a tubercle bacillus phospholipid antibody via a coupling agent to immobilized red blood cells and a human bodily fluid or the dilute liquid thereof into contact with each other, observing the agglutinated image thereof and detecting the tubercle bacillus phospholipid with high accuracy. CONSTITUTION:The live red blood cells obtd. from a goat, rabbit, etc. is subjected to a gaseous CO treatment and formalin is added thereto to obtain the immobilized red blood cells. The tubercle bacillus phospholipid antibody is conjugated via the coupling agent such as tannic acid to such red blood cells to obtain the sensitized red blood cells. The sensitized blood cells are stable for >=1 year if the blood cells are suspended in a physiological salt soln. contg. PBS and BSA added with sodium azide and are preserved in a frozen chamber. The sensitized blood cell suspension is brought into contact with a sample serum or the dilute liquid thereof and the agglutinated image thereof is observed. The agglutinated image of the double-double dilute liquid of the sample contg. standard phospholipid is compared with the agglutinated image of the sample and the measurement of the concn. of the phospholipid in the same with good accuracy by using a slight amt. of the sample is made possible.